Global Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Ocular Pain Market Analysis and Size
The global ocular pain market is expected to witness significant growth during the forecast period. The market comprises of numerous key players who are focusing on research and development activities to formulate novel drugs and involve new therapies for the effective treatment. The major market players are involved in licensing and patenting due to the increasing demand for novel and effective drugs across the globe. The rising awareness among people for eye-related diseases and more and more cases of ocular migraine is further boosting the market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global ocular pain market in the forecast period 2022-2029. The expected CAGR of global ocular pain market is tend to be around 8% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Ocular pain which is also known as eye pain, usually occurs due to mild irritation, but it is rarely a symptom of a serious condition. Normally the pain gets subsided without medicine or further treatment, and recovers automatically by the self-immune system. Although, ocular pain having primary ophthalmic disorders requires timely treatment. Often ocular pain is treated with eye drops and topical steroids or NSAIDs.
Ocular Pain Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Aerie Pharmaceuticals, Inc. (U.S.), Bausch Health (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Alcon (Switzerland), Bayer AG (Germany), Carl Zeiss Meditec AG (Germany), HumanOptics Holding AG (Germany), Sun Pharmaceuticals Industries Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S.), Bausch Health Companies Inc. (U.S.), Ocular Therapeutix, Inc. (U.S.), IACTA Pharmaceuticals, Inc (U.S.)
|
|
Market Opportunities
|
|
Global Ocular Pain Market Dynamics
Drivers
- Increase in Elderly Population
The global ocular pain market is expected to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the global ocular pain market is a replication of the growing elderly population, as people aged over 60 years frequently develop conditions in which eyes have reduced elasticity, affecting the normal functioning. This boost the market growth.
- Increased Product Launches
Rising strategies such as new product launches could help the major market players gain a competitive edge over the other players. For instance, Dextenza is the first FDA-approved intracanalicular insert, which volunteers the drug to the surface of the eye without the requirement for eye drops. Another one is Lotemax SM which was approved in February 2019, to treat postoperative inflammation and pain following ocular surgery. This boosts the market growth
Opportunities
- Rising Government Initiatives
The growing adoption of initiatives, policies, and programs by the government authorities and many public organizations is improving access to affordable vision care, which is anticipated to drive the market size.
- Increasing Demand for Retail Pharmacies
The rise in the number of vitreoretinal disorders medications being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries can create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of skilled healthcare personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global ocular pain market over a forecast period.
- High Cost
The huge expenditure associated with the treatment of vitreoretinal disorders surely hamper the market growth.
This global ocular pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ocular pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Ocular Pain Market
The Covid-19 pandemic greatly affected the market due to reduction in number of patient visits in hospitals and clinics for ocular disorders and interruption of numerous alternative procedures and outpatient visits. The trending work from home culture during the onset of the COVID-19 pandemic and even post that has led to a sedentary lifestyle and online working patterns which involve more and more exposure to screens. Although, the market is expected to recover with continuation of activities across various domains and approval and administration of Covid-19 vaccines.
Global Ocular Pain Market Scope
The global ocular pain market is segmented on the basis of disease type, application, route of administration , drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Ocular Pain with Eye Diseases
- Ocular Pain without Primary Eye Diseases
Application
- Conjunctivitis
- Corneal Abrasion
- Blepharitis
- Sty
- Iritis
- Sinusitis
- Migraines
- Glaucoma
- Others
Route of Administration
- Topical
- Periocular
- Intraocular
- Oral
- Others
Drug Type
- Prescription
- Over the Counter
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Ocular Pain Market Regional Analysis/Insights
The global ocular pain market is analysed and market size insights and trends are provided by disease type, application, route of administration , drug type, distribution channel and end-user as referenced above.
The major countries covered in the global ocular pain market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global ocular pain market throughout the forecasted period due to the highest number of geriatric and vulnerable populations.
North America dominates the market due to increasing cases of ophthalmic disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Ocular Pain Market Share Analysis
The global ocular pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global ocular pain market.
Key players operating in the global ocular pain market include:
- Aerie Pharmaceuticals, Inc. (U.S.)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Alcon (Switzerland)
- Bayer AG (Germany)
- Amgen Inc. (U.S.)
- Carl Zeiss Meditec AG (Germany)
- HumanOptics Holding AG (Germany)
- Sun Pharmaceuticals Industries Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Alvogen (U.S.)
- Bausch Health Companies Inc. (U.S.)
- Ocular Therapeutix, Inc. (U.S.)
- IACTA Pharmaceuticals, Inc (U.S.)
SKU-